WO03063812(特表2005-523260)
"1. A process for producing（製造）a pharmaceutical composition comprising the steps: (a) forming（生成）a feed solution comprising a drug, a concentration-enhancing polymer and a solvent; (b) directing said feed solution to a spray- drying apparatus comprising a drying chamber, atomizing（霧化）means for atomizing said feed solution into droplets in said drying chamber, a source of heated drying gas for drying said droplets and dried product collection means; (c) atomizing said feed solution into droplets in said drying chamber by said atomizing means, said droplets having an average diameter of at least 50 Am and a Dlo of at least 10 Am ; (d) contacting said droplets with said heated drying gas to form particulates（微粒子を生成）of a solid amorphous dispersion of said drug and said concentration-enhancing polymer; and (e) collecting said particulates wherein said concentration-enhancing polymer is present in said solution in a sufficient amount so that said solid amorphous dispersion provides concentration enhancement of said drug in a use environment relative to a control composition consisting essentially of an equivalent amount of said drug alone."
US9803230(特表2016-514453)
"16. A method for enriching nucleic acids from a sample, the method comprising: a) providing; i) a sample suspected of comprising nucleic acids, ii) magnetic microparticles suitable for binding nucleic acids, and iii) an aqueous-based separation gel, b) contacting the sample with the magnetic microparticles for a length of time and under conditions suitable for any nucleic acids in the sample to bind to the magnetic microparticles to create loaded magnetic microparticles（負荷磁気微粒子を生成）; c) depositing the loaded magnetic microparticles in a vessel, layering an aqueous-based separation gel over the lysed loaded magnetic microparticles and further layering a buffer over the aqueous-based separation gel; and d) drawing the loaded magnetic microparticles through the aqueous-based separation gel with a magnetic field into a buffer."
WO2010043892(特表2012-505305)
"25. The use of polymers, as defined in claim 18 or any claim dependent thereon, either singly or in combination, to partition into the surface of biodegradable polymer spheres during particle preparation, thus generating microparticles（微粒子を生成）having highly controllable colloidal stability and biomaterial properties."
WO2009002579(特表2010-531207)
"With the bus interface circuitry 215 allowing each functional block to communicate using the protocol established for the bus 190, it now becomes a relatively simple endeavor to make changes to the various functional blocks to fix circuit errors, and/or to upgrade the IC 200 for use in next-generation IPGs. This is because each of the blocks' circuitry can be changed without worries that（心配が無い）such changes will necessitate other changes in related blocks, or otherwise perturb the operation of other blocks."
WO2016087861(特表2017-536198)
" This operating mode may be appropriate if there is no concern about（心配がない）unused oxygenation gas leaking out of the oxygenator, for instance during extracorporeal ventilation without anaesthesia."
WO2016133508(特表2017-509240)
"Preemption may be performed based on relative priorities and latency sensitivity of packets transmitted over the virtual lanes. Thus, rules may be provided to configure multiple levels of priority and to specify the amount of bandwidth that may be consumed by higher priority traffic such that lower priority traffic is not starved of（不足）bandwidth. Higher-priority traffic, which may generally be of lower bandwidth, may therefore be given priority over other traffic without concern that（心配なく）it could deprive the other traffic of bandwidth if the higher priority traffic were to exceed its allocated bandwidth limits."
